Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

European Journal of Cancer

Volumn 44, Issue 17, 2008, Pages 2542-2545

  van Herpen, C M L ^a   Locati, L D ^b   Buter, J ^c   Thomas, J ^d   Bogaerts, J ^e   Lacombe, D ^e   de Mulder, P ^a   Awada, A ^f   Licitra, L ^b   Bernier, J ^g   Vermorken, J B ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e EORTC DATA CENTER   (Belgium)

^f JULES BORDET INSTITUTE   (Belgium)

^g CLINIQUE DE GENOLIER   (Switzerland)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adenoid cystic carcinoma; Gemcitabine; Head and neck cancer; Salivary gland tumours

Indexed keywords

GEMCITABINE;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, ADENOID CYSTIC; DEOXYCYTIDINE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 55249089179     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.08.014     Document Type: Article

References (13)

1. Sessions R.B., Harrison L.B., and Forastiere A. Tumors of the salivary glands and paragangliomas. In: Devita V.T., Hellman S., and Rosenberg S.A. (Eds). Principles and practice of oncology (2000), Lippincott-Raven Publishers, Philadelphia, PA
2. Spiro R.H., Huvos A.G., and Strong E.W. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128 (1974) 512-520
3. Laurie S.A., and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24 (2006) 2673-2678
4. Green M.R. Gemcitabine safety overview. Semin Oncol 23 5 S 10 (1996) 32-35
5. Therasse P., Arbuck S.G., Eisenhauer A.E., et al. New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
6. National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1; 1999. Available at: http://ctep.info.nih.gov.
7. Pfeffer M.R., Talmi Y., Catane R., et al. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43 (2007) 33-36
8. Hotte S.J., Winquist E.W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess Margaret hospital phase II consortium study. J Clin Oncol 23 (2005) 590-595
9. Glisson B.S., Blumenschein G., Francisco M., et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23 (2005) 508 [Suppl; abstr 5532]
10. Haddad R., Colevas A.D., Krane J.F., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 39 (2003) 724-777
11. Argiris A., Goldwasser M.A., Burtness B., et al. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an eastern cooperative oncology group study. J Clin Oncol 23 (2005) 5474-5483
12. Licitra L., Locati L., Potepan P., et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study. J Clin Oncol (2006) [ASCO Ann Meeting Proc; No.18S:5547]
13. Agulnik M., Cohen E.W.E., Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984